IZ

Investor profile

Ido Zairi

Venture capital

United States2known investments

Ido Zairi is a venture capital investor based in United States. The known portfolio counts 2 companies: Splisense and Vensica Therapeutics.

Is Ido Zairi a fit for your startup?

Paste your website. AI checks the fit and scores every other investor too.

Investment focus

Contacts

ido***@***.comPhone number on fileLinkedIn profile on fileAvailable after registration.
Get contact

Ido Zairi portfolio companies (2)

  • Splisense
  • Vensica Therapeutics

Investor Profile

The known portfolio sits in sector Healthcare, and focus areas Biotech and Therapeutics.

Stage-wise, the known deals cluster around Seed and Series A rounds.

Reviewing the investment history helps decide whether there is a realistic fit before reaching out.

Similar investors

Showing 20 of 98

Frequently asked questions

Who is Ido Zairi?

Ido Zairi is a venture capital investor based in United States with 2 known investments on file, among them Splisense and Vensica Therapeutics. The sections above list the sectors and stages attached to that record.

What does Ido Zairi invest in?

Listed sectors include Healthcare; listed focus areas include Biotech and Therapeutics. Those tags come from the companies attached to this profile, so they read as a record of what has been backed rather than a stated preference for what comes next.

What stage does Ido Zairi invest at?

The known deals of Ido Zairi include Seed and Series A rounds. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.

How do I contact Ido Zairi?

An email address, a phone number and a LinkedIn page are on file for Ido Zairi. The address stays masked on this page and is readable inside RaiseHunt after you create an account.

Skip the browsing. Let AI find your ideal investors in one minute.

Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.

Data: RaiseHunt investor dataset · Snapshot 6 September 2026 · How this data is built · Report a correction or request removal